The company will nominate Britt Meelby Jensen for election as a new Board member at BioPorto’s Annual General Meeting on April 13, 2018.
Today it is announced that BioPorto’s Board of Directors will nominate Britt Meelby Jensen for election as a new Board member at BioPorto’s Annual General Meeting on April 13, 2018.
Britt Meelby Jensen (Danish citizen, born 1973) has extensive global commercial and general management experiences from working in the life sciences area over the past 16 years at Novo Nordisk, Dako and Zealand Pharma. Since 2015 Britt has been the CEO of Zealand Pharma A/S, a medium sized biotech company listed on NASDAQ in Copenhagen and New York. Britt Meelby Jensen holds a Master of Science from Copenhagen Business School and a Master in Business Administration from Solvay Business School in Brussels, Belgium.
Thomas Magnussen, Chairman of the Board, says: “We are delighted with the opportunity to nominate Britt for election to the Board at the upcoming general meeting. She brings unique international management skills and commercial insights that are complementary to the existing team. We look forward to welcoming Britt on the Board.”
For further information, please contact:
Thomas Magnussen, Chairman of the Board of Directors
Telephone +45 4529 0000, e-mail investor@bioporto.com
About BioPorto
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.
